The estimated Net Worth of Gary Sender is at least $1.07 Million dollars as of 8 March 2021. Mr. Sender owns over 28,775 units of Nabriva Therapeutics Plc stock worth over $40,861 and over the last 8 years he sold NBRV stock worth over $0. In addition, he makes $1,032,480 as Chief Financial Officer at Nabriva Therapeutics Plc.
Gary has made over 5 trades of the Nabriva Therapeutics Plc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 28,775 units of NBRV stock worth $303,576 on 8 March 2021.
The largest trade he's ever made was exercising 28,775 units of Nabriva Therapeutics Plc stock on 8 March 2021 worth over $303,576. On average, Gary trades about 1,626 units every 37 days since 2017. As of 8 March 2021 he still owns at least 28,775 units of Nabriva Therapeutics Plc stock.
You can see the complete history of Mr. Sender stock trades at the bottom of the page.
Gary L. Sender serves as Chief Financial Officer of the Company. Mr. Sender previously served as our chief financial officer from May 2016 until the Redomiciliation. Prior to joining Nabriva Austria, he served as chief financial officer and executive vice president at Synergy Pharmaceuticals from 2015 to 2016. From 2009 until 2015, Mr. Sender served as senior vice president, Finance at Shire plc., supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. He was responsible for financial management and support of all commercial areas of Shire's Specialty Pharmaceutical and Rare Disease businesses, with an emphasis on resource allocation, financial forecasting, business cases and mergers and acquisitions. Prior to joining Shire, Mr. Sender was the founding CFO of Tengion, Inc. Mr. Sender also spent 15 years in a number of leadership roles within Merck. Mr. Sender received his B.S. from Boston University and an M.B.A from Carnegie-Mellon University.
As the Chief Financial Officer of Nabriva Therapeutics Plc, the total compensation of Gary Sender at Nabriva Therapeutics Plc is $1,032,480. There are 4 executives at Nabriva Therapeutics Plc getting paid more, with Colin Broom having the highest compensation of $2,044,990.
Gary Sender is 58, he's been the Chief Financial Officer of Nabriva Therapeutics Plc since 2019. There are 7 older and 8 younger executives at Nabriva Therapeutics Plc. The oldest executive at Nabriva Therapeutics Plc is George Talbot, 72, who is the Independent member of the Supervisory Board.
Gary's mailing address filed with the SEC is C/O SCHRODINGER, INC.,, 1540 BROADWAY, 24TH FLOOR, NEW YORK, NY, 10036.
Over the last 8 years, insiders at Nabriva Therapeutics Plc have traded over $3,221,169 worth of Nabriva Therapeutics Plc stock and bought 436,925 units worth $1,215,585 . The most active insiders traders include Capital Viii, Llc Vivo, Bioventures Cayman Ltd Hbm, and Charles A Jr Rowland. On average, Nabriva Therapeutics Plc executives and independent directors trade stock every 33 days with the average trade being worth of $23,562. The most recent stock trade was executed by Daniel D Burgess on 2 August 2022, trading 11,341 units of NBRV stock currently worth $2,155.
nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products. nabriva was incorporated as a spin-off from sandoz gmbh antibiotics research institute (abri) in vienna, austria and commenced operations in february 2006. the new organization included small molecule assets, including pleuromutilin structure activity relationships (sar) knowledge and was focused on synthesis of pleuromutilins for systemic human use. following identification of our lead compound lefamulin and based on the clinical results of lefamulin for acute skin and skin structure infections. we believed that targeted in vitro spectrum of activity for the common pathogens causing community acquired bacterial pneumonia (cabp), wo
Nabriva Therapeutics Plc executives and other stock owners filed with the SEC include: